Zevra Therapeutics, Inc. (ZVRA)
NASDAQ: ZVRA · Real-Time Price · USD
8.71
+0.05 (0.58%)
At close: Dec 5, 2025, 4:00 PM EST
8.88
+0.17 (1.95%)
After-hours: Dec 5, 2025, 7:59 PM EST
Zevra Therapeutics Stock Forecast
Stock Price Forecast
The 7 analysts with 12-month price forecasts for Zevra Therapeutics stock have an average target of 21.71, with a low estimate of 18 and a high estimate of 26. The average target predicts an increase of 149.25% from the current stock price of 8.71.
Analyst Consensus: Strong Buy
* Price targets were last updated on Nov 6, 2025.
Analyst Ratings
The average analyst rating for Zevra Therapeutics stock from 7 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jul '25 | Aug '25 | Sep '25 | Oct '25 | Nov '25 | Dec '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 6 | 6 | 6 | 6 | 4 | 4 |
| Buy | 3 | 4 | 4 | 4 | 3 | 3 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 9 | 10 | 10 | 10 | 7 | 7 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Canaccord Genuity | Canaccord Genuity | Strong Buy Maintains $25 → $24 | Strong Buy | Maintains | $25 → $24 | +175.55% | Nov 6, 2025 |
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Maintains $29 → $24 | Buy | Maintains | $29 → $24 | +175.55% | Nov 6, 2025 |
| JMP Securities | JMP Securities | Buy Maintains $19 → $18 | Buy | Maintains | $19 → $18 | +106.66% | Aug 13, 2025 |
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Maintains $25 → $29 | Buy | Maintains | $25 → $29 | +232.95% | Jul 10, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Initiates $26 | Strong Buy | Initiates | $26 | +198.51% | Jul 2, 2025 |
Financial Forecast
Revenue This Year
102.30M
from 23.61M
Increased by 333.25%
Revenue Next Year
147.01M
from 102.30M
Increased by 43.70%
EPS This Year
1.31
from -2.28
EPS Next Year
0.57
from 1.31
Decreased by -56.45%
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 107.3M | 176.8M | ||||
| Avg | 102.3M | 147.0M | ||||
| Low | 96.1M | 128.8M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 354.5% | 72.8% | ||||
| Avg | 333.3% | 43.7% | ||||
| Low | 307.2% | 25.9% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 1.42 | 1.12 | ||||
| Avg | 1.31 | 0.57 | ||||
| Low | 1.14 | 0.28 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | - | -13.9% | ||||
| Avg | - | -56.4% | ||||
| Low | - | -78.2% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.